证券日报网讯桂林三金10月17日在互动平台回答投资者提问时表示,目前公司产品BC006单抗注射液项目,即将完成Ⅰ期临床试验。如果取得关键性突破,公司会按照深交所要求进行披露。

(文章来源:证券日报)
本文地址: http://www.jiaotongmi.com/article/20819.html
文章来源:admin
版权声明:除非特别标注,否则均为本站原创文章,转载时请以链接形式注明文章出处。
2025-11-13admin
2025-11-12admin
2025-11-11admin
2025-11-10admin
2025-11-09admin
2025-11-08admin
2025-11-07admin
2025-11-06admin
2025-11-05admin
2025-11-04admin
2025-09-08admin
2025-09-08admin
2025-09-13admin
2025-09-17admin
2025-09-08admin
2025-09-17admin
2025-09-09admin
2025-09-09admin
2025-09-13admin
2025-09-11admin
2025-09-11admin
2025-09-17admin
2025-09-08admin
2025-09-08admin
2025-09-10admin
2025-09-09admin
2025-09-08admin
2025-09-08admin
2025-09-08admin
2025-09-08admin
扫码二维码
获取最新动态
